[1] Seibel MJ, Cooper MS, Zhou H. Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives [J]. Lancet Diabetes End, 2013, 1(1):59-70. [2] Amiche MA, Albaum JM, Tadrous M, et al. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials [J]. Osteoporos Int, 2016, 27(5):1709-1718. [3] 谢小伟,裴福兴,康鹏德,等.不同剂量、多疗程地塞米松对大鼠成骨细胞生物活性及Wnt信号通路的影响[J].中国骨质疏松杂志, 2013, 19(8):823-828. [4] Ofek O, Attarnamdar M, Kram V, et al. CB2 cannabinoid receptor targets mitogenic gi protein-cyclin D1 axis in osteoblasts [J]. J Bone Miner Res, 2011, 26(2):308-316. [5] Komori T. Glucocorticoid signaling and bone biology [J]. Horm Metab Res, 2016, 48(11):755. [6] Ossola CA, Surkin PN, Mohn CE, et al. Anti-inflammatory and osteoprotective effects of cannabinoid-2 receptor agonist HU-308 in a rat model of lipopolysaccharide-induced periodontitis [J]. J Periodontol, 2016, 87(6):1. [7] 江新葵,李佳亿,冯青,等.HU-308药物缓释涂层对骨质疏松大鼠种植体周围骨改建相关因子表达的影响[J].中华老年口腔医学杂志,2016,14(2):109-114. [8] Ofek O, Karsak M, Leclerc N, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass [J]. Proc Natl Acad Sci U S A, 2006, 103(3):696-701. [9] Weitzmann MN. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis [J]. Scientifica, 2013, 2013:125705. [10] Brennan-Speranza TC, Henneicke H, Gasparini SJ, et al. Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism [J]. J Clin Invest, 2012, 122(11):4172-4189. [11] Jr CM. Biology of RUNX2 and cleidocranial dysplasia [J]. J Craniofac Surg, 2013, 24(1):130-133. [12] 孙龙,侯玉东,薛鹏飞,等.骨形态发生蛋白7在高糖环境下对成骨细胞分化的影响[J].口腔医学研究, 2016, 32(9):973-977. [13] Jones TJ, Adapala RK, Geldenhuys WJ, et al. Primary cilia regulates the directional migration and barrier integrity of endothelial cells through the modulation of hsp27 dependent actin cytoskeletal organization [J]. J Cell Physiol, 2012, 227(1):70-76. |